a673 (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
96
Structured Review
ATCC
a673
A673, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 592 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a-673/A-673/pm42318649-234-16-17
Average 96 stars, based on 592 article reviews
A673, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 592 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a-673/A-673/pm42318649-234-16-17
Average 96 stars, based on 592 article reviews
a673 - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
Mutagenesis:Article Title: Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma Article Snippet: er cell bank. SYO-1 and Mojo cell lines were shared by G Schwartz (Columbia University) ( 57 ) and M. Ladanyi (Memorial Sloan Kettering Cancer Center). Other cells used in this work were obtained from Control:Article Title: Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma Article Snippet: er cell bank. SYO-1 and Mojo cell lines were shared by G Schwartz (Columbia University) ( 57 ) and M. Ladanyi (Memorial Sloan Kettering Cancer Center). Other cells used in this work were obtained from Transgenic Assay:Article Title: Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma Article Snippet: er cell bank. SYO-1 and Mojo cell lines were shared by G Schwartz (Columbia University) ( 57 ) and M. Ladanyi (Memorial Sloan Kettering Cancer Center). Other cells used in this work were obtained from Derivative Assay:Article Title: Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma Article Snippet: er cell bank. SYO-1 and Mojo cell lines were shared by G Schwartz (Columbia University) ( 57 ) and M. Ladanyi (Memorial Sloan Kettering Cancer Center). Other cells used in this work were obtained from Modification:Article Title: Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma Article Snippet: er cell bank. SYO-1 and Mojo cell lines were shared by G Schwartz (Columbia University) ( 57 ) and M. Ladanyi (Memorial Sloan Kettering Cancer Center). Other cells used in this work were obtained from Cell Culture:Article Title: Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma Article Snippet: er cell bank. SYO-1 and Mojo cell lines were shared by G Schwartz (Columbia University) ( 57 ) and M. Ladanyi (Memorial Sloan Kettering Cancer Center). Other cells used in this work were obtained from Enzyme-linked Immunosorbent Assay:Article Title: Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma Article Snippet: er cell bank. SYO-1 and Mojo cell lines were shared by G Schwartz (Columbia University) ( 57 ) and M. Ladanyi (Memorial Sloan Kettering Cancer Center). Other cells used in this work were obtained from Protein Concentration:Article Title: Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma Article Snippet: er cell bank. SYO-1 and Mojo cell lines were shared by G Schwartz (Columbia University) ( 57 ) and M. Ladanyi (Memorial Sloan Kettering Cancer Center). Other cells used in this work were obtained from Concentration Assay:Article Title: Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma Article Snippet: er cell bank. SYO-1 and Mojo cell lines were shared by G Schwartz (Columbia University) ( 57 ) and M. Ladanyi (Memorial Sloan Kettering Cancer Center). Other cells used in this work were obtained from SDS Page:Article Title: Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma Article Snippet: er cell bank. SYO-1 and Mojo cell lines were shared by G Schwartz (Columbia University) ( 57 ) and M. Ladanyi (Memorial Sloan Kettering Cancer Center). Other cells used in this work were obtained from In Vitro:Article Title: Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma Article Snippet: er cell bank. SYO-1 and Mojo cell lines were shared by G Schwartz (Columbia University) ( 57 ) and M. Ladanyi (Memorial Sloan Kettering Cancer Center). Other cells used in this work were obtained from shRNA:Article Title: Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma Article Snippet: er cell bank. SYO-1 and Mojo cell lines were shared by G Schwartz (Columbia University) ( 57 ) and M. Ladanyi (Memorial Sloan Kettering Cancer Center). Other cells used in this work were obtained from Expressing:Article Title: Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma Article Snippet: er cell bank. SYO-1 and Mojo cell lines were shared by G Schwartz (Columbia University) ( 57 ) and M. Ladanyi (Memorial Sloan Kettering Cancer Center). Other cells used in this work were obtained from RNA Sequencing Assay:Article Title: Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma Article Snippet: er cell bank. SYO-1 and Mojo cell lines were shared by G Schwartz (Columbia University) ( 57 ) and M. Ladanyi (Memorial Sloan Kettering Cancer Center). Other cells used in this work were obtained from Sequencing:Article Title: Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma Article Snippet: er cell bank. SYO-1 and Mojo cell lines were shared by G Schwartz (Columbia University) ( 57 ) and M. Ladanyi (Memorial Sloan Kettering Cancer Center). Other cells used in this work were obtained from |